Resistance index to epoetin alfa and to darbepoetin-alfa in chronic hemodialysis patients: A cohort study;Estudio de dos cohortes de pacientes para evaluar el índice de resistencia a epoetina alfa y a darbepoetin alfa en pacientes en hemodiálisis crónica

Nefrologia

Volumn 27, Issue 3, 2007, Pages 340-349

  Pérez García, Rafael ^a   Rodriguez Benitez P ^a   Jofre, R ^a   Lopez Gomez J M ^a   Villaverde, Ma T ^b   Blanco, A ^b   Blanco, S ^c   Sanchez M ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Dialcentro ^*

^c Departamento Médico

Author keywords

Anemia; Darbepoetin alfa; Epoetin; Hemodialysis; Resistance index

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; DRUG DERIVATIVE; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; ERYTHROPOIESIS; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

ADULT; AGED; ANEMIA; C-REACTIVE PROTEIN; COHORT STUDIES; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 34848814179     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pérez García R, Rodríguez Benítez P, Villaverde M, Valderrábano F: El índice de respuesta a la eritropoyetina (IRE) es un buen marcador de adecuación en diálisis. Nefrología 21: 606-7, 2001.
2. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 14 (Supl. 5): 1-50, 1999.
3. Allon M, Kleinman K, Walczyk M: Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 72: 546-55, 2002.
4. MacDougall I, Gray S, Elston O: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392-5, 1999.
5. Scott S: Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 22: 160S-5S, 2002.
6. Locatelli F, Canaud B, Giacardy F: Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 18: 362-9, 2003.
7. Roger S, Cooper B: What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology 9: 223-8, 2004.
8. Nissenson A, Swan S, Lindberg J: Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40: 110-8, 2004.
9. Vanrenterghem Y, Barany P, Mann J: Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62: 2167-75, 2002.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (5): 373-83, 1987.
11. López Gómez J, Valderrábano F: Resistencia al tratamiento con eritropoyetina. Nefrología 19 (Supl. 3): 4-9, 1999.
12. Sitter T, Bergner A, Schiffl H: Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15: 1207-11, 2000.
13. Hsu P, Lin C, Yu C: Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 17: 693-700, 2004.
14. Pérez García R, Verde E, Sanz A: r-HuEPO resistance and dialysate chloramine contamination in patients on hemodialysis. Nephron 86: 222-3, 2000.
15. Villaverde M, Pérez García R, Verde E: La polisulfona de alta permeabilidad mejora la respuesta de la anemia a la eritropoyetina en hemodialisis. Nefrología 19: 161-7, 1999.
16. Gunnell J, Yeun J, Depner T: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33: 63-72, 1999.
17. Movilli E, Cancarini G, Zani R: Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 16: 111-4, 2001.
18. Locatelli F, Del Vecchio L, Andrulli S: The modality of dialysis treatment: does it influence the response to erythropoietin treatment? Nephrol Dial Transplant 16: 1971-4, 2001.
19. MacDougall I, Matcham J, Gray S: Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 18: 576-81, 2003.
20. Locatelli F, Olivares J, Walker R: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60: 741-7, 2001.
21. Jadoul M, Vanrenterghem Y, Foret M: Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19: 898-903, 2004.
22. Ling B, Walczyk M, Agarwal A: Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 63: 327-34, 2005.
23. Martínez Castelao A, Reyes A, Valdés F: Estudio multicéntrico de darbepoetin alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica en diálisis. Nefrología 23: 114-24, 2003.
24. Suranyi M, Lindberg J, Navarro J: Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 23: 106-11, 2003.
25. Toto R, Pichette V, Navarro J: Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 24: 453-60, 2004.
26. Carretero Dios D, López Gómez JM, Pérez García R, Rodríguez Benítez P, Gutiérrez Sánchez MJ, Jofré R: Comparación de las vías subcutánea e intravenosa en el tratamiento con epoetin-alfa de la anemia en la IRC. Nefrología 23 (Supl. 6): 70, 2003.
27. Villaverde M, Luño J, Verde E: Estudio de la supervivencia en un centro de diálisis. Seguimiento de 10 años (1986-1996). Nefrología 17: 532-4, 1997.